The Finnish Medicines Agency and the Ministry of Health in Luxembourg have granted marketing authorization for Alimera Sciences, Inc.’s drug ILUVIEN®, used in the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered unresponsive to available therapies.
ILUVIEN is now approved for marketing in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States, and is commercially available in the United Kingdom, Germany and Portugal.
ILUVIEN is a sustained release intravitreal implant used to treat patients with DME. Each ILUVIEN implant provides a therapeutic effect of up to 36 months.
SOURCE Alimera Sciences, Inc.
